ArticleScientific reports2026
Nisin and rutin as potential coating agents for iron oxide nanoparticles for enhanced theranostic applications against cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron oxide nanoparticles (IONPs) have proven to be of therapeutic potential against cancer. The feature of the surface coating can affect important properties of IONPs; it is therefore critical for further understanding how these materials react to physiological conditions, which is still needed to fully exploit the potential of IONPs for their theranostic applications. In this study, we explored the therapeutic potential of rutin and nisin conjugated IONPs as anticancer agents. One important hallmark of many cancers is the overexpression of the endoplasmic reticulum-resident chaperone, GRP78, and its translocation to many cellular compartments, including the cell membrane. We explored the potential binding affinity of rutin and nisin against the substrate-binding domain β (SBDβ) of GRP78. The results show promising results for both nisin and rutin, with more enhanced binding capability of the former due to its extended structure (peptide in nature), forming more non-bonded interactions with the GRP78 surface. Our findings pave the way for the use of these coating agents against the cell-exposed chaperone, GRP78, to alleviate its chemoresistance characteristics in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.